Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
Bellerophon Therapeutics, Inc. (the “Company”) issued a press release on August3, 2017 announcing agreement with the U.S. Food and Drug Administration on the Phase 2 study design for INOpulse® in pulmonary hypertension associated with Interstitial Lung Disease, or PH-ILD. The Company also announced it will be host a key opinion leader event on PH-ILD in New York City on Wednesday, August 9, 2017. A copy of this press release is attached hereto as Exhibit 99.1. The information included in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated August 3, 2017 (furnished and not filed for purposes of Item 7.01) |
Bellerophon Therapeutics, Inc. ExhibitEX-99.1 2 a8-kaugust2017ildex991.htm EXHIBIT 99.1 Exhibit Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)Company to Host Key Opinion Leader Event on PH-ILD in New York CityWarren,…To view the full exhibit click here
About Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial.
